HARRISBURG – Today, PA Chamber President and CEO Luke Bernstein joined leaders from Johnson & Johnson in Ambler as the company announced its plans to invest more than $1 billion into a new cell therapy manufacturing facility in the Commonwealth. Afterward, he issued the following statement:
“Today’s announcement is the latest in a growing series of major investments that underscore Pennsylvania’s renewed competitiveness and momentum. Johnson & Johnson’s decision to expand its footprint here marks a significant win for the Commonwealth and for the future of American life sciences leadership.
“Johnson & Johnson’s announcement builds on recent momentum, including Eli Lilly’s $3.5 billion commitment in the Lehigh Valley, and reinforces that when Pennsylvania advances smart, pro‑growth policies, employers respond with real investment.
“This investment is the result of focused, bipartisan efforts in recent years by the General Assembly and the Shapiro administration to strengthen Pennsylvania’s business climate. Pro-growth tax reforms and meaningful permitting improvements are making our state more competitive for large-scale, transformative projects.
“I want to thank Governor Shapiro and his team, particularly Secretary Rick Siger and Chief Transformation Officer Ben Kirchner, for their hard work and leadership in landing this critical investment. J&J could have selected anywhere to invest, but they deliberately chose Pennsylvania. With world‑class research institutions, a highly skilled workforce, and a strong life sciences ecosystem, Pennsylvania has the fundamentals to lead in next‑generation innovation. By continuing to advance policies that strengthen our competitive edge, the Commonwealth is positioning itself as a global hub for life‑saving scientific breakthroughs and 21st‑century manufacturing.”